181 related articles for article (PubMed ID: 7537665)
1. Strontium-89 (Metastron) in the treatment of prostate cancer metastatic to bone.
Porter AT
Eur Urol; 1994; 26 Suppl 1():20-5. PubMed ID: 7537665
[TBL] [Abstract][Full Text] [Related]
2. A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone.
McEwan AJ; Amyotte GA; McGowan DG; MacGillivray JA; Porter AT
Eur Urol; 1994; 26 Suppl 1():26-31. PubMed ID: 7537666
[TBL] [Abstract][Full Text] [Related]
3. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience.
Lee CK; Aeppli DM; Unger J; Boudreau RJ; Levitt SH
Am J Clin Oncol; 1996 Apr; 19(2):102-7. PubMed ID: 8610630
[TBL] [Abstract][Full Text] [Related]
4. Palliation of bone pain in patients with metastatic cancer using strontium-89 (Metastron).
Kan MK
Cancer Nurs; 1995 Aug; 18(4):286-91. PubMed ID: 7545083
[TBL] [Abstract][Full Text] [Related]
5. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.
Porter AT; McEwan AJ
Semin Oncol; 1993 Jun; 20(3 Suppl 2):38-43. PubMed ID: 7684865
[TBL] [Abstract][Full Text] [Related]
6. Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group.
Bolger JJ; Dearnaley DP; Kirk D; Lewington VJ; Mason MD; Quilty PM; Reed NS; Russell JM; Yardley J
Semin Oncol; 1993 Jun; 20(3 Suppl 2):32-3. PubMed ID: 7684863
[No Abstract] [Full Text] [Related]
7. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement.
Kraeber-Bodéré F; Campion L; Rousseau C; Bourdin S; Chatal JF; Resche I
Eur J Nucl Med; 2000 Oct; 27(10):1487-93. PubMed ID: 11083537
[TBL] [Abstract][Full Text] [Related]
8. An overview of current clinical experience with strontium-89 (Metastron).
Bos SD
Prostate Suppl; 1994; 5():23-6. PubMed ID: 8172712
[TBL] [Abstract][Full Text] [Related]
9. A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone.
McEwan AJ; Amyotte GA; McGowan DG; MacGillivray JA; Porter AT
Nucl Med Commun; 1994 Jul; 15(7):499-504. PubMed ID: 7970425
[TBL] [Abstract][Full Text] [Related]
10. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.
Porter AT; McEwan AJ; Powe JE; Reid R; McGowan DG; Lukka H; Sathyanarayana JR; Yakemchuk VN; Thomas GM; Erlich LE
Int J Radiat Oncol Biol Phys; 1993 Apr; 25(5):805-13. PubMed ID: 8478230
[TBL] [Abstract][Full Text] [Related]
11. Strontium 89 therapy for the palliation of pain due to osseous metastases.
Robinson RG; Preston DF; Schiefelbein M; Baxter KG
JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
[TBL] [Abstract][Full Text] [Related]
12. [The role of systemic radiotherapy in the combined treatment for hormone-resistant prostate cancer].
Solodky VA; Pavlov AY; Panshin GA; Gafanov RA; Fastovets SV; Isaev TK
Vopr Onkol; 2015; 61(1):31-3. PubMed ID: 26016142
[TBL] [Abstract][Full Text] [Related]
13. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases.
Kasalický J; Krajská V
Eur J Nucl Med; 1998 Oct; 25(10):1362-7. PubMed ID: 9818274
[TBL] [Abstract][Full Text] [Related]
14. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
Brundage MD; Crook JM; Lukka H
Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
[TBL] [Abstract][Full Text] [Related]
15. [Bone metastases treated with radiopharmaceuticals].
Giammarile F
Bull Cancer; 2013 Nov; 100(11):1223-7. PubMed ID: 24409472
[TBL] [Abstract][Full Text] [Related]
16. Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre's 10-year experience.
Windsor PM
Clin Oncol (R Coll Radiol); 2001; 13(3):219-27. PubMed ID: 11527299
[TBL] [Abstract][Full Text] [Related]
17. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer.
Pons F; Herranz R; Garcia A; Vidal-Sicart S; Conill C; Grau JJ; Alcover J; Fuster D; Setoain J
Eur J Nucl Med; 1997 Oct; 24(10):1210-4. PubMed ID: 9323260
[TBL] [Abstract][Full Text] [Related]
18. [Strontium-89 for bone metastases from prostate cancer: an update].
Zhao WW; Xie P; Deng HF
Zhonghua Nan Ke Xue; 2010 Mar; 16(3):269-72. PubMed ID: 20369560
[TBL] [Abstract][Full Text] [Related]
19. Strontium chloride Sr 89 for treating pain from metastatic bone disease.
Nightengale B; Brune M; Blizzard SP; Ashley-Johnson M; Slan S
Am J Health Syst Pharm; 1995 Oct; 52(20):2189-95. PubMed ID: 8564588
[TBL] [Abstract][Full Text] [Related]
20. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review.
Bauman G; Charette M; Reid R; Sathya J
Radiother Oncol; 2005 Jun; 75(3):258-70. PubMed ID: 16299924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
